跳至主要内容
临床试验/DRKS00018931
DRKS00018931已完成3 期

Remote Ischemic Preconditioning (RIPC) versus sham-control for reduction of ischemia-reperfusion injury of the Liver after liver surgery in patients with pre-damaged liver: a prospective, randomized controlled, triple-blind, clinical phase III monocenter trial - RIP

Medizinische Fakultät Mannheim0 个研究点目标入组 102 人开始时间: 2019年11月22日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
102

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Persons meeting the following criteria may be included in the study:
  • Known pre-damage to the liver (e.g. liver cirrhosis (Child Pugh A and B), steatosis, fibrosis, s/p chemotherapy, other pathologies leading to liver damage)
  • Planned elective liver resection or dissection of the liver tissue (so-called in situ split) with subsequent resection
  • Signed informed consent
  • Age =18 years

排除标准

  • Persons meeting any of the following criteria cannot be included in the study:
  • Patients not able to give informed consent
  • Liver cirrhosis Child Pugh C
  • Patients presenting with the following contraindications to the study intervention (RIPC): arterial occlusive disease (AOD), infections or wounds on the upper extremity, poorly controlled diabetes mellitus, or deep vein thrombosis of the upper extremity
  • Patients in whom a Pringle maneuver is unlikely due to the type of procedure or extent of resection (e.g. very small and/or peripheral resections)

研究者

相似试验